Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07169578 · ClinicalTrials.gov registry record · Phase 3

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

A Phase 3 study of Alzheimers Disease, sponsored by Hoffmann-La Roche.

Recruiting
Registry status
Phase 3
Development phase
800
Enrollment target
20
Study locations

NCT07169578 is a Phase 3 study of Alzheimers Disease that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 800 participants, below the 4,056-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07169578, a Phase 3 study of Alzheimers Disease, is actively recruiting participants, sponsored by Hoffmann-La Roche.

RECRUITING
Registry status
Phase 3
Development phase
800 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).

Conditions Studied

Alzheimers Disease

Interventions

  • OTHER Placebo
  • DRUG Trontinemab

Study Locations (20)

Florida

  • K2 Medical Research - The Villages - Lady Lake
  • K2 Medical Research, LLC - Maitland
  • Renstar Medical Research - Ocala
  • Axiom Brain Health LLC - Tampa
  • Charter Research - Lady Lake/The Villages - The Villages
  • Alzheimer?s Research and Treatment Center - Wellington
  • Conquest Research, LLC - Winter Park

California

  • Inglewood Clinicals - Inglewood
  • Irvine Center for Clinical Research - Irvine
  • UCSF - Memory and Aging Center - San Francisco
  • Syrentis Clinical Research - Santa Ana

New York

  • Basil Clinical - Laurelton
  • Adams Clinical Harlem - New York

Arizona

  • Banner Sun Health Research Institute - Sun City

Georgia

  • Accel Research Sites-NeuroStudies - Decatur

Hawaii

  • Hawaii Pacific Neuroscience - Honolulu

Illinois

  • RE:Cognition (Chicago) - Chicago

Massachusetts

  • Boston Center for Memory - Newton

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2025-09-17
Est. Completion 2028-06-07
Phase Phase 3

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07169578

The ClinicalTrials.gov registry entry for NCT07169578 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,056-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (80% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07169578 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, New York.

Frequently Asked Questions

What is clinical trial NCT07169578 about?

NCT07169578 is a clinical study titled "A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease". The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).

What is the current status of trial NCT07169578?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2025-09-17. Estimated completion is 2028-06-07.

What conditions does trial NCT07169578 study?

This clinical trial studies the following conditions: Alzheimers Disease.

What interventions are being tested in trial NCT07169578?

The interventions under investigation include: Placebo (OTHER), Trontinemab (DRUG).

Who is sponsoring clinical trial NCT07169578?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07169578 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimers Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.